Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · STAAR Surgical (STAA)

STAAR Surgical Q3 sales rose 6.9% to $94.7M, but net income fell to $8.9M

Mixed Impact 3 of 5 earnings Written later

STAAR Surgical reported third quarter 2025 results for the period ended September 26, 2025. Net sales rose 6.9% from a year earlier to $94.7 million, helped by $25.9 million from a December 2024 China shipment that was paid in full this quarter, while net income fell to $8.9 million, or $0.18 per diluted share, from $10.0 million, or $0.20 per share. Because the company is being acquired by Alcon Inc., it will not hold a conference call on the results.

Key points

  • Net sales were $94.7 million, up 6.9% from $88.6 million a year earlier, including $25.9 million from the December China Shipment.
  • Net sales excluding China were $38.9 million, up 7.7% year over year.
  • Net income was $8.9 million, or $0.18 per diluted share, versus $10.0 million, or $0.20 per share, a year earlier; the company recorded $5.9 million in merger transaction costs.
  • Adjusted EBITDA was $34.6 million, or $0.68 per share, compared with $16.2 million, or $0.33 per share, a year earlier.

The filing

CompanySTAAR Surgical (STAA)
Form8-K, current report
Filed with the SECNov 5, 2025, 4:02 PM ET
Accession number0001193125-25-266857

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.